BioImagene launches digital pathology solutions suite in Europe BioImagene.

European demand for digital pathology reaches a tipping stage, and provided our successes in the usa over the past season, we are poised to determine a leadership placement in Europe. Our important differentiators include the state-of-the-art option business and portfolio model, as well as an exceptionally responsive support and program organization.’ BioImagene’s solutions are more developed in the usa and clients and collaborators consist of prestigious Academic Medical Centers such as for example Cedars Sinai INFIRMARY, Johns Hopkins, Stanford University INFIRMARY, University of Pennsylvania College of Medication, University of Miami, University of Nebraska, in addition to marquee Reference Labs including Laboratory Corp, Clarient Labs, Bio-Reference Labs, CorePlus, and Dahl-Chase Pathology Associates.It has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a good safety, tolerability and medication distribution profile. ContraVir intends to build up CMX157 for HBV and HIV. M. Michelle Berrey, M.D., M.P.H., Chief and President Executive Officer of Chimerix, commented, As we continue our focus on developing our lead medical asset brincidofovir, we remain self-confident in the potential of CMX157 and believe that significant value will be regarded with continued development by ContraVir and its own experienced team.